Ethyl 2,3-dihydro-5-oxo-1H,5H-benzo[ij]quinolizine-6-carboxylate | 444188-20-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: Ethyl 2,3-dihydro-5-oxo-1H,5H-benzo[ij]quinolizine-6-carboxylate
• 英文别名: ethyl 2-oxo-1-azatricyclo[7.3.1.05,13]trideca-3,5(13),6,8-tetraene-3-carboxylate
• CAS: 444188-20-9
• 化学式: C₁₅H₁₅NO₃
• 分子量: 257.28
• InChiKey: WGJLSXRAGUEHPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Ethyl 2,3-dihydro-5-oxo-1H,5H-benzo[ij]quinolizine-6-carboxylate 、 N-(甲氧甲基)-N-(三甲基硅甲基)苄胺 、 三氟乙酸 在 碳酸氢钠 、 Brine 、 potassium carbonate 、 ethyl acetate n-hexane 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以to afford 36.6 g (96%) of the title compound of Part B as an off white solid的产率得到(+/-)-cis ethyl 10-benzyl-8-oxo-5,6,9,10,11,11a-hexahydro-4H-pyrido[3,2,1-ij]pyrrolo[3,4-c]quinoline-8a(8H)-carboxylate
  参考文献：
  名称：

  SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS

  摘要：

  本发明涉及由结构式（I）1表示或其药学上可接受的盐形式的某些新型化合物，其中R1、R6a、R6b、R7、R8、R9、X、b、m和n在此描述。本发明还涉及包含这些新型化合物作为活性成分的制药配方以及利用这些化合物和它们的配方治疗某些疾病。本发明的化合物是5-羟色胺激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症、焦虑症、抑郁症、精神病、精神分裂症、睡眠障碍、性功能障碍、偏头痛、与头痛有关的疾病、社交恐惧症以及胃肠道疾病，如胃肠道运动功能障碍。

  公开号：

  US20040092502A1

文献信息

• Substituted pyrroloquinolines and pyridoquinolines as serotinin agonists and antagonists
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：US06777406B2

  公开（公告）日：2004-08-17

  The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein is R1, R6a, R6b, R7, R8, R9, X, b, m, and n are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

  本发明涉及由结构式（I）表示或其药学上可接受的盐形式的某些新化合物，其中R1、R6a、R6b、R7、R8、R9、X、b、m和n如本文所述。本发明还涉及包含这些新化合物作为活性成分的制药配方以及新化合物及其配方在治疗某些疾病方面的用途。本发明的化合物是5-羟色胺激动剂和拮抗剂，对于控制或预防包括肥胖症、焦虑症、抑郁症、精神病、精神分裂症、睡眠障碍、性功能障碍、偏头痛、头痛相关的疾病、社交恐惧症以及胃肠道障碍如胃肠道运动功能障碍在内的中枢神经系统疾病具有用处。
• US6777406B2
  申请人：——

  公开号：US6777406B2

  公开（公告）日：2004-08-17
• SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS
  申请人：——

  公开号：US20040092502A1

  公开（公告）日：2004-05-13

  The present invention is directed to certain novel compounds represented by structural Formula (I) 1 or pharmaceutically acceptable salt forms thereof, wherein R 1 , R 6a , R 6b , R 7 , R 8 , R 9 , X, b, m, and n are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

  本发明涉及由结构式（I）1表示或其药学上可接受的盐形式的某些新型化合物，其中R1、R6a、R6b、R7、R8、R9、X、b、m和n在此描述。本发明还涉及包含这些新型化合物作为活性成分的制药配方以及利用这些化合物和它们的配方治疗某些疾病。本发明的化合物是5-羟色胺激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症、焦虑症、抑郁症、精神病、精神分裂症、睡眠障碍、性功能障碍、偏头痛、与头痛有关的疾病、社交恐惧症以及胃肠道疾病，如胃肠道运动功能障碍。